臨床外科66巻7号

2011年07月発行

特集 術前薬物療法は乳癌手術を縮小させるか

術前ホルモン療法と乳房温存術

著者： 指宿睦子¹ 山本豊¹ 岩瀬弘敬¹

所属機関： ¹熊本大学医学部附属病院乳腺・内分泌外科

ページ範囲：P.904 - P.912

文献概要

【ポイント】

◆術前ホルモン療法の薬剤としてアロマターゼ阻害薬（AI）は有効であり，奏効度や乳房温存率はタモキシフェン（TAM）と比較して優れた成績を示している．

◆乳房温存率改善以外の術前ホルモン療法の意義や至適投与期間などについては不明であり，今後解決すべき課題が多い．

◆術前ホルモン療法はトランスレーショナル・リサーチの宝庫であり，PEPIやKi67を用いた予後予測モデル・因子についての新しい知見に加えて，臨床試験と連動した分子生物学的解析が行われており，今後の個別化治療への応用が期待される．

参考文献

1）Iwase H：Current topics and perspectives on the use of aromatase inhibitors in the treatment of breast cancer. Breast Cancer 15：278-290, 2008

2）Eiermann W, Paepke S, Appfelstaedt J, et al：Preoperative treatment of postmenopausal breast cancer patients with letrozole：a randomized double-blind multicenter study. Ann Oncol 12：1527-1532, 2001

3）Smith IE, Dowsett M, Ebbs SR, et al：Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination：the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen（IMPACT）multicenter double-blind randomized trial. J Clin Oncol 23：5108-5116, 2005

4）Cataliotti L, Buzdar AU, Noguchi S, et al：Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer：the Pre-Operative “Arimidex” Compared to Tamoxifen（PROACT）trial. Cancer 106：2095-2103, 2006

5）Semiglazov VF, Semiglazov E：Exemestane vs tamoxifen as neoadjuvant endocrine therapy for post menopausal women with ER＋breast cancer（T2N1-2, T3N0-1, T4N0M0）. J Clin Oncol 23：530, 2005

6）Ellis M, Suman V, Hoog J, et al：ACOSOG Z1031：A randomized neoadjuvant comparison between letrozole（LET）, anastrozole（ANA）and exemestane（EXE）for postmenopausal women with ER rich stage 2/3 breast cancer：biomarker outcomes and the predictive value of the baseline PAM50 based intrinsic subtype. SABCS. 2010

7）Semiglazov VF, Semiglazov VV, Dashyan GA, et al：Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer 110：244-254, 2007

8）Alba LC, Calvo J, Albanell J, et al：Chemotherapy（CT）versus Hormone Therapy（HT）as Neoadjuvant Treatment in Luminal Breast Cancer：A Multi-center, Randomized Phase Ⅱ Study. J Clin Oncol 28：15s, 2010（Suppl；abstr 500）

9）Krainick-Strobel UE, Lichtenegger W, Wallwiener D, et al：Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer：a phase Ⅱb/Ⅲ trial to investigate optimal duration of preoperative endocrine therapy. BMC Cancer 8：62, 2008

10）Toi M, Saji S, Masuda N, et al：Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition. Cancer Sci. Jan 13（Epub ahead of print）

11）Gazet JC, Ford HT, Gray R, et al：Estrogen-receptor-directed neoadjuvant therapy for breast cancer：results of a randomised trial using formestane and methotrexate, mitozantrone and mitomycin C（MMM）chemotherapy. Ann Oncol 12：685-691, 2001

12）Torrisi R, Bagnardi V, Pruneri G, et al：Antitumour and biological effects of letrozole and GnRH analogue as primary therapy in premenopausal women with ER and PgR positive locally advanced operable breast cancer. Br J Cancer 97：802-808, 2007

13）Sagara N, Masuda N, Kinoshita T, et al：The STAGE Study：APhase Ⅲ Comparison of Anastrozole Plus Goserelin With Tamoxifen Plus Goserelin asPre-operative Treatments in Pre-menopausal Breast Cancer Patients. SABCS. 2010, P1-12-03

14）Takei H, Suemasu K, Inoue K, et al：Multicenter phase Ⅱ trial of neoadjuvant exemestane for postmenopausal patients with hormone receptor-positive, operable breast cancer：Saitama Breast Cancer Clinical Study Group（SBCCSG-03）. Breast Cancer Res Treat 107：87-94, 2008

15）Akashi-Tanaka S, Omatsu M, Shimizu C, et al：Favorable outcome in patients with breast cancer in the presence of pathological response after neoadjuvant endocrine therapy. Breast 16：482-488, 2007

16）山本　豊，岩瀬弘敬：ホルモン感受性，非感受性　アロマターゼ阻害と抗腫瘍効果．最新医学 65：1374-1387，2010

17）Ellis MJ, Tao Y, Luo J, et al：Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst 100：1380-1388, 2008

18）Ellis MJ, Coop A, Singh B, et al：Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer：evidence from a phase Ⅲ randomized trial. J Clin Oncol 19：3808-3816, 2001

19）Ellis MJ, Lin L, Crowder R, et al：Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer. Breast Cancer Res Treat 119：379-390, 2010

20）Ellis MJ, Miller WR, Tao Y, et al：Aromatase expression and outcomes in the P024 neoadjuvant endocrine therapy trial. Breast Cancer Res Treat 116：371-378, 2009

21）Yamashita H, Takahashi S, Ito Y, et al：Predictors of response to exemestane as primary endocrine therapy in estrogen receptor-positive breast cancer. Cancer Sci 100：2028-2033, 2009

22）Miller WR, Larionov A, Renshaw L, et al：Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole. J Clin Oncol 27：1382-1387, 2009

23）Harvell DM, Richer JK, Singh M, et al：Estrogen regulated gene expression in response to neoadjuvant endocrine therapy of breast cancers：tamoxifen agonist effects dominate in the presence of an aromatase inhibitor. Breast Cancer Res Treat 112：489-501, 2008

24）Miller WR：Clinical, pathological, proliferative and molecular responses associated with neoadjuvant aromatase inhibitor treatment in breast cancer. J Steroid Biochem Mol Biol 118：273-276, 2009